Colosia A, Njue A, Bajwa Z, Dragon E, Robinson RL, Sheffield KM, Thakkar S, Richeimer SH. The burden of metastatic cancer-induced bone pain: a narrative review. J Pain Res. 2022 Oct 25;2022(15):3399-412. doi: 10.2147/JPR.S371337
Foraster M. Respiratory effects of exposure to environmental noise levels and noise annoyance. BRN Reviews. 2021 Jan;7(1):4-26. doi: 10.23866/BRNRev:2020-0002
Abellan A, Casas M. In utero exposure to organic pollutants and lung function in the offspring. BRN Reviews. 2021;7(1):62-79. doi: 10.23866/BRNRev:2020-0004
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.